Current status of hematopoietic stem cell transplantation in Taiwan

Bone Marrow Transplantation
P M ChenT J Chiou

Abstract

In Taiwan, hematopoietic SCT (HSCT) has been used to treat patients with hematological diseases since 1983. Since then, more than 2200 patients have undergone HSCT in 15 large hospitals. The disease entities included acute leukemia in 37% of cases, non-Hodgkin's lymphoma in 26%, CML in 10%, multiple myeloma in 7% and severe aplastic anemia in 6%. The conditioning regimens used were mainly myeloablative (84% of cases). Non-myeloablative regimens were fludarabine-based. The average age of allogeneic recipients was at least 10 years older than those in the era before their application. The grafts of all patients were derived from peripheral blood in 85% of cases, BM in 13% and cord blood (CB) in 2%. Forty percent of HSCT patients received autologous grafts, whereas more than 25% of allogeneic HSCT patients received grafts from unrelated donors, and overall, there were more than 200 Taiwan HSCT recipients. Currently, CB has been used successfully in pediatric patients with thalassemia major and also in adult patients with hematological malignancy. After transplantation, there was a relatively lower prevalence of acute GVHD. However, a relatively higher proportion of hepatitis B carriers in the recipients had led to a higher inciden...Continue Reading

References

Sep 11, 2001·Bone Marrow Transplantation·S C KuP C Yang
Nov 15, 2002·International Journal of Hematology·Tsung Dao Lee
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tang-Her JaingRobert Chow
Aug 30, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Say-Bee PohPo-Min Chen
Sep 9, 2005·International Journal of Hematology·Giun-Yi HungBetau Hwanga
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Liang-Tsai HsiaoPo-Min Chen

❮ Previous
Next ❯

Citations

Mar 2, 2010·Bone Marrow Transplantation·A YoshimiUNKNOWN Asia-Pacific Blood and Marrow Transplantation Group (APBMT)
Jul 31, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tso-Fu WangRuey-Ho Kao
Jan 20, 2015·Bone Marrow Transplantation·A A HamidiehA Ghavamzadeh
Aug 15, 2009·Current Opinion in Hematology·Alois Gratwohl, Helen Baldomero
Nov 30, 2018·JAMA Oncology·Tzu-Chuan HuangYi-Ying Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.